(CNN) – The United States is one step closer to having a fourth COVID-19 vaccine.
Novavax’s vaccine is protein-based and created in more of a traditional way. It uses technology that differs from the three vaccines already in use in the U.S.
”The more we have the better,” emergency physician at Brigham and Women’s Hospital Dr. Jeremy Faust said.
Novavax says two doses of its vaccine provides about 90% efficacy in protecting people 18 and over against COVID-19. However, the clinical trials were done before omicron became the dominant variant in the U.S.
The most common adverse reactions included headache,